Sponsor name | Trials on EUCTR | Trials due to report results | % Reported | Trials with inconsistent data | Major? |
---|---|---|---|---|---|
Novartis | 1545 | 976 | 99.9% | 335 | major |
GlaxoSmithKline | 1197 | 725 | 100.0% | 370 | major |
Pfizer | 909 | 573 | 99.5% | 228 | major |
Merck Sharp & Dohme (MSD) | 869 | 507 | 100.0% | 209 | major |
Roche | 806 | 414 | 98.8% | 187 | major |
Sanofi S.A. | 765 | 393 | 100.0% | 292 | major |
Astrazeneca | 748 | 415 | 97.8% | 135 | major |
Johnson & Johnson | 589 | 334 | 99.7% | 140 | major |
Eli Lilly | 490 | 319 | 99.4% | 77 | major |
Medical University of Vienna | 458 | 280 | 93.9% | 35 | major |
Amsterdam UMC | 413 | 69 | 39.1% | 54 | major |
Bristol-Myers Squibb | 411 | 219 | 100.0% | 105 | major |
Boehringer Ingelheim | 400 | 311 | 100.0% | 52 | major |
Hospitals of Paris (AP-HP) | 354 | 63 | 27.0% | 52 | major |
Bayer | 345 | 248 | 100.0% | 60 | major |
Amgen Inc | 308 | 201 | 100.0% | 64 | major |
Novo Nordisk | 283 | 183 | 100.0% | 50 | major |
KU Leuven | 274 | 192 | 95.3% | 7 | major |
Radboud University Medical Centre | 274 | 93 | 87.1% | 59 | major |
Abbvie | 271 | 133 | 99.2% | 64 | major |
Gilead Sciences Inc | 269 | 172 | 100.0% | 66 | major |
Rigshospitalet | 268 | 152 | 52.0% | 26 | major |
Takeda | 260 | 152 | 100.0% | 65 | major |
No Sponsor Name Given | 248 | 84 | 67.9% | 25 | major |
Erasmus University | 239 | 15 | 80.0% | 30 | major |
UCB | 238 | 123 | 100.0% | 91 | major |
Aarhus University | 224 | 130 | 66.2% | 16 | major |
Charité-Universitätsmedizin Berlin | 214 | 163 | 100.0% | 8 | major |
Agostino Gemelli University Polyclinic | 196 | 17 | 11.8% | 113 | major |
University of Groningen | 189 | 17 | 70.6% | 12 | major |
Leiden University | 183 | 19 | 36.8% | 17 | major |
Merck KGaA | 179 | 123 | 100.0% | 34 | major |
Utrecht University | 171 | 26 | 57.7% | 46 | major |
IRCCS Ospedale San Raffaele | 165 | 55 | 100.0% | 12 | major |
University College London | 163 | 90 | 98.9% | 8 | major |
Astellas | 158 | 110 | 100.0% | 31 | major |
Ghent University | 157 | 68 | 52.9% | 42 | major |
Servier Laboratories | 154 | 116 | 100.0% | 22 | major |
Celgene | 150 | 73 | 100.0% | 35 | major |
Allergan | 147 | 105 | 99.0% | 30 | major |
University of Oxford | 146 | 86 | 100.0% | 0 | major |
Imperial College London | 145 | 103 | 100.0% | 2 | major |
Karolinska University Hospital | 140 | 26 | 42.3% | 13 | major |
Medical University of Graz | 139 | 91 | 75.8% | 9 | major |
Biogen | 139 | 88 | 96.6% | 30 | major |
IRCCS Azienda Ospedaliero-Universitaria di Bologna | 135 | 5 | 100.0% | 34 | major |
Novartis Vaccines | 132 | 65 | 100.0% | 63 | major |
Eisai Inc. | 131 | 69 | 100.0% | 44 | major |
Helsinki University | 130 | 36 | 33.3% | 11 | major |
Pierre Fabre S.A. | 122 | 99 | 99.0% | 7 | major |
Oslo University Hospital | 122 | 23 | 47.8% | 9 | major |
Odense University Hospital | 120 | 76 | 92.1% | 16 | major |
University of Birmingham | 118 | 53 | 100.0% | 5 | major |
Chiesi Farmaceutici S.p.A | 117 | 78 | 100.0% | 23 | major |
Vertex Pharmaceuticals, Inc. | 117 | 60 | 100.0% | 41 | major |
Shire | 115 | 79 | 100.0% | 23 | major |
European Organisation for the Research and Treatment of Cancer (EORTC) | 111 | 65 | 98.5% | 18 | major |
Hospices Civils de Lyon | 110 | 25 | 24.0% | 11 | major |
Abbott | 109 | 87 | 96.6% | 18 | major |
King’s College London | 108 | 73 | 98.6% | 6 | major |
Université libre de Bruxelles | 106 | 25 | 68.0% | 11 | major |
Herlev and Gentofte Hospital | 105 | 63 | 71.4% | 12 | major |
National Cancer Institute Italy (Istituto Nazionale dei Tumori) | 105 | 4 | 50.0% | 23 | major |
Teva | 100 | 76 | 100.0% | 15 | major |
Actelion Pharmaceuticals Ltd | 99 | 65 | 100.0% | 26 | major |
Ipsen | 96 | 63 | 100.0% | 20 | major |
H. Lundbeck A/S | 95 | 72 | 98.6% | 15 | major |
Regeneron Pharmaceuticals Inc. | 93 | 32 | 100.0% | 31 | major |
Unicancer | 92 | 17 | 88.2% | 4 | major |
CSL Behring | 88 | 52 | 100.0% | 29 | major |
Karolinska Institutet | 88 | 36 | 77.8% | 15 | major |
Daiichi Sankyo | 86 | 48 | 100.0% | 18 | major |
Incyte Corporation | 86 | 25 | 96.0% | 16 | major |
Alexion Pharmaceuticals, Inc | 85 | 37 | 97.3% | 30 | major |
Maastricht University | 85 | 25 | 36.0% | 24 | major |
University of Munich (Ludwig-Maximilians) | 84 | 50 | 74.0% | 6 | major |
Fundació Clínic per a la Recerca Biomèdica | 84 | 7 | 28.6% | 30 | major |
Otsuka | 82 | 55 | 100.0% | 16 | major |
Innsbruck Medical University | 82 | 54 | 92.6% | 5 | major |
University of Cologne | 82 | 53 | 98.1% | 0 | major |
Guy's and St Thomas' NHS Foundation Trust | 82 | 50 | 96.0% | 3 | major |
Antoni van Leeuwenhoek Hospital | 82 | 6 | 66.7% | 7 | major |
Genentech | 80 | 60 | 100.0% | 10 | major |
CHU de Toulouse | 77 | 17 | 5.9% | 18 | major |
Alcon | 76 | 44 | 100.0% | 31 | major |
University of Dundee | 74 | 69 | 100.0% | 1 | major |
Vrije Universiteit Brussel | 74 | 8 | 62.5% | 7 | major |
Menarini Group | 72 | 58 | 100.0% | 7 | major |
University of Leeds | 72 | 52 | 98.1% | 0 | major |
University Hospital Tübingen | 72 | 45 | 86.7% | 5 | major |
Bispebjerg Hospital | 71 | 46 | 54.3% | 7 | major |
NHS Greater Glasgow and Clyde | 71 | 40 | 100.0% | 2 | major |
Vall d'Hebron University Hospital | 71 | 22 | 86.4% | 15 | major |
European Institute of Oncology | 71 | 1 | 0.0% | 17 | major |
LEO Pharma A/S | 70 | 56 | 100.0% | 11 | major |
Technical University of Munich | 70 | 46 | 100.0% | 13 | major |
The Newcastle upon Tyne Hospitals NHS Foundation Trust | 69 | 56 | 92.9% | 1 | major |
Galderma R&D | 69 | 54 | 98.1% | 8 | major |
Heidelberg University Hospital | 67 | 40 | 92.5% | 3 | major |
Cliniques Universitaires Saint-Luc | 67 | 19 | 89.5% | 28 | major |
Hospital de la Santa Creu i Sant Pau | 67 | 12 | 66.7% | 13 | major |
ACCORD (University of Edinburgh & NHS Lothian) | 66 | 44 | 97.7% | 2 | major |
Queen Mary University of London | 65 | 42 | 100.0% | 5 | major |
Baxter | 64 | 49 | 95.9% | 8 | major |
University Erlangen-Nuremberg | 64 | 35 | 74.3% | 6 | major |
University of Nottingham | 63 | 57 | 100.0% | 1 | major |
Manchester University NHS Foundation Trust | 63 | 53 | 100.0% | 1 | major |
Mario Negri Institute | 63 | 31 | 100.0% | 15 | major |
University of Turku | 63 | 18 | 50.0% | 3 | major |
Gothenburg University | 63 | 16 | 37.5% | 10 | major |
CHU Clermont-Ferrand | 63 | 13 | 0.0% | 7 | major |
Almirall S.A. | 62 | 51 | 100.0% | 6 | major |
Ferring Pharmaceuticals | 60 | 54 | 100.0% | 3 | major |
The Royal Marsden NHS Foundation Trust | 60 | 29 | 82.8% | 2 | major |
CHU de Bordeaux | 59 | 12 | 16.7% | 11 | major |
Sapienza University of Rome | 59 | 2 | 50.0% | 7 | major |
Fondazione Giovanni Pascale | 59 | 1 | 0.0% | 12 | major |
Hannover Medical School | 58 | 49 | 93.9% | 3 | major |
Hvidovre Hospital | 58 | 34 | 44.1% | 7 | major |
AOU Policlinico di Modena | 58 | 8 | 12.5% | 24 | major |
HOVON Foundation | 58 | 5 | 100.0% | 7 | major |
Policlinico San Matteo | 58 | 5 | 0.0% | 38 | major |
University Hospitals of Leicester NHS Trust | 56 | 45 | 97.8% | 5 | major |
University of Hamburg | 56 | 30 | 93.3% | 0 | major |
Belfast Health and Social Care Trust | 55 | 46 | 97.8% | 0 | major |
Mundipharma | 55 | 45 | 93.3% | 5 | major |
Octapharma AG | 54 | 34 | 100.0% | 14 | major |
Skåne University Hospital | 54 | 15 | 40.0% | 10 | major |
King's College Hospital NHS Foundation Trust | 53 | 41 | 97.6% | 2 | major |
Johannes Gutenberg University of Mainz | 53 | 36 | 72.2% | 5 | major |
BioMarin Pharmaceutical Inc | 53 | 23 | 95.7% | 11 | major |
University of Antwerp | 53 | 7 | 42.9% | 8 | major |
University of Freiburg | 52 | 27 | 88.9% | 3 | major |
Barts Health NHS Trust | 51 | 44 | 97.7% | 4 | major |
University Hospital Southampton NHS Foundation Trust | 51 | 20 | 65.0% | 2 | major |
Goethe University | 51 | 19 | 68.4% | 4 | major |
CHU de Nantes | 51 | 13 | 69.2% | 5 | major |
Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) | 51 | 3 | 0.0% | 23 | major |
Cambridge University Hospitals NHS Foundation Trust | 50 | 42 | 95.2% | 0 | major |
Dresden University of Technology | 50 | 29 | 93.1% | 5 | major |